The role of amifostine on late normal tissue damage induced by pelvic radiotherapy with concomitant gemcitabine: An in vivo study

Medical Oncology

Volumn 26, Issue 4, 2009, Pages 402-408

  Dinçbaş, Fazilet Öner ^a   Öksüz, Didem Çolpan ^a   Atalar, Banu ^b   Altug, Tuncay ^c   İlvan, Şennur ^a   Gedik, Nursal ^d   Özel, Sevda ^a   Koca, Sedat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b AMERICAN HOSPITAL   (Turkey)

^c ISTANBUL BILIM UNIVERSITY   (Turkey)

^d KASIMPASA MILITARY HOSPITAL   (Turkey)

Author keywords

Amifostine; Gemcitabine; Late normal tissue toxicity; Pelvic radiotherapy

Indexed keywords

AMIFOSTINE; COLLAGEN; GEMCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER; BLADDER DISEASE; BLADDER FIBROSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL INFILTRATION; COLITIS; CONTROLLED STUDY; CYSTITIS; FIBROSIS; FOLLOW UP; HISTOPATHOLOGY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; PELVIS; PLASMA CELL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION PROTECTION; RAT; RECTUM; SINGLE DRUG DOSE;

EID: 70949099965     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9136-1     Document Type: Article

References (34)

1. Constine LS, Williams JP, Morris M, Rubin P, Okunieff P. Late effects of cancer treatment on normal tissues. In: Perez CA, Brady LW, Halperin EC, SchmIdt-Ullrich RK, editors. Principles and practice of radiation oncology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2004. p. 357-90.
2. S Mose, et al. 2000 Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines Anticancer Res 20 A 401 5 1:CAS:528:DC%2BD3cXisl2nt7c%3D 10769687
3. DS Shewach TM Hahn E Chang LW Hertel TS Lawrence 1994 Metabolism of 2′2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells Cancer Res 54 3218 23 1:CAS:528:DyaK2cXkslehs70%3D 8205542
4. L Milas, et al. 1999 Enhancement of tumor radioresponse in vivo by gemcitabine Cancer Res 59 107 14 1:CAS:528:DyaK1MXmsFOnsA%3D%3D 9892194
5. KA Mason, et al. 1999 Maximizing therapeutic gain with gemcitabine and fractionated radiation Int J Radiat Oncol Biol Phys 44 1125 35 10.1016/S0360-3016(99)00134-0 1:CAS:528:DyaK1MXltVWrsL4%3D 10421547 (Pubitemid 29342915)
6. MT Fields, et al. 2000 Radiosensitization produced in vivo by once vs twice weekly 2′,2′-difluoro-2′-deoxycytidine (gemcitabine) Int J Radiat Oncol Biol Phys 47 785 91 10.1016/S0360-3016(00)00447-8 10.1016/S0360-3016(00)00447-8 1:CAS:528:DC%2BD3cXjs1CgtLk%3D 10837965 (Pubitemid 30317500)
7. A Eisbruch, et al. 2001 Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study J Clin Oncol 19 792 9 1:CAS:528:DC%2BD3MXhtlGrt70%3D 11157033
8. AW Blackstock, et al. 1999 Phase I trial of twice weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer J Clin Oncol 17 7 2208 12 1:CAS:528:DyaK1MXkvVSmurk%3D 10561277
9. MS Talamonti, et al. 2000 Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity J Clin Oncol 18 3384 9 1:CAS:528:DC%2BD3cXnslWjsr4%3D 11013279
10. M Ikeda S Okada K Tokuuye H Ueno T Okusaka 2002 A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer Br J Cancer 86 1551 4 10.1038/sj.bjc.6600256 10.1038/sj.bjc.6600256 1:CAS:528:DC%2BD38XkvVaitb4%3D 12085203 (Pubitemid 34628107)
11. CJ McGinn, et al. 2001 Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer J Clin Oncol 19 4202 8 1:CAS:528:DC%2BD38XhslWqtg%3D%3D 11709563
12. JM Pipas, et al. 2001 Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas Int J Radiat Oncol Biol Phys 50 1317 22 10.1016/S0360-3016(01)01580-2 1:CAS:528:DC%2BD3MXls1ehsLc%3D 11483344 (Pubitemid 32727811)
13. L Trodella, et al. 2002 Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer J Clin Oncol 20 804 10 10.1200/JCO.20.3.804 10.1200/JCO.20.3.804 1:CAS:528:DC%2BD38XhsVGmtL8%3D 11821464 (Pubitemid 34111389)
14. E Kent, et al. 2004 Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a Phase I trial J Clin Oncol 22 13 2540 5 10.1200/JCO.2004.10.070 10.1200/JCO.2004.10.070 1:CAS:528:DC%2BD2cXpsVWks7o%3D 15226322 (Pubitemid 41103741)
15. VK Sangar, et al. 2005 Phase I study of conformal radiotherapy with concurrent Gemcitabine in locally advanced bladder cancer Int J Radiat Oncol Biol Phys 61 2 420 5 10.1016/j.ijrobp.2004.05.074 1:CAS:528: DC%2BD2MXmtleqsQ%3D%3D 15667962 (Pubitemid 40164436)
16. P Pattaranutaporn, et al. 2001 Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage III B cervical carcinoma Gynecol Oncol 81 404 7 10.1006/gyno.2001.6197 10.1006/gyno.2001.6197 1:CAS:528:DC%2BD3MXjslansr4%3D 11371129 (Pubitemid 32494654)
17. CN Andreassen C Grau JC Lindegaard 2003 Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy Semin Radiat Oncol 13 1 62 72 10.1053/srao.2003.50006 10.1053/srao.2003.50006 12520465 (Pubitemid 36173261)
18. DR Cassatt CA Fazenbaker CM Bachy MS Hanson 2002 Preclinical modeling of improved amifostine (ethyol) use in radiation therapy Semin Radiat Oncol 12 1 97 102 10.1053/srao.2002.31382 10.1053/srao.2002.31382 11917293
19. JP Delaney ME Bonsack I Felemovicius 1994 Radioprotection of the rat small intestine with topical WR-2721 Cancer 74 2379 84 10.1002/1097- 0142(19941015)74:8<2379::AID-CNCR2820740825>3.0.CO;2-J 10.1002/1097-0142(19941015)74:8<2379::AID-CNCR2820740825>3.0.CO;2-J 1:CAS:528:DyaK2MXitVWqsb8%3D 7922989 (Pubitemid 24322296)
20. H Ito ML Meistrich HT Barkley HD Thames L Milas 1986 Protection of acute and late radiation damage of the gastrointestinal tract by WR-2721 Int J Radiat Oncol Biol Phys 12 211 9 1:CAS:528:DyaL28Xhs1CnsLw%3D 3949572
21. S Wadler, et al. 1996 The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix Semin Oncol 23 8 64 8 1:CAS:528:DyaK28XmsFCmtLY%3D 8783670
22. N Mitsuhashi I Takahashi M Takahashi 1993 Clinical study of radioprotective effects of amifostine (YM-08310, WR-2721) on long-term outcome for patients with cervical cancer Int J Radiat Oncol Biol Phys 26 407 11 1:STN:280:DyaK3s3ptlGmtg%3D%3D 8390418
23. T Liu Y Liu S He Z Zhang MM Kligerman 1992 Use of radiation with or without WR-2721 in advanced rectal cancer Cancer 69 2820 5 10.1002/1097- 0142(19920601)69:11<2820::AID-CNCR2820691130>3.0.CO;2-T 10.1002/1097-0142(19920601)69:11<2820::AID-CNCR2820691130>3.0.CO;2-T 1:STN:280:DyaK383ktVGktg%3D%3D 1315211
24. MM Kligerman, et al. 1992 Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721 Int J Radiat Oncol Biol Phys 22 799 802 1:STN:280:DyaK387osVKhsQ%3D%3D 1312078
25. J Kouvaris, et al. 2003 Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy Strahlenther Onkol 179 167 74 10.1007/s00066-003-0970-y 10.1007/s00066-003-0970-y 12627259 (Pubitemid 36313771)
26. H Athanassiou, et al. 2003 Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial Int J Radiat Oncol Biol Phys 56 1154 60 10.1016/S0360-3016(03) 00187-1 10.1016/S0360-3016(03)00187-1 1:CAS:528:DC%2BD3sXkvVClu7o%3D 12829154 (Pubitemid 36794050)
27. AD Sasse LG Clark EC Sasse OA Clark 2006 Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis Int J Radiat Oncol Biol Phys 64 3 784 91 10.1016/j.ijrobp.2005.06. 023 1:CAS:528:DC%2BD28XhtVCrtrg%3D 16198504 (Pubitemid 43183575)
28. AA Yavuz F AydIn MN Yavuz E Ilis F Ozdemir 2001 Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice weekly gemcitabine advanced pancreatic cancer Int J Radiat Oncol Biol Phys 51 974 81 10.1016/S0360-3016(01)01737-0 1:CAS:528:DC%2BD3MXotFWjsbc%3D 11704320 (Pubitemid 33026427)
29. TP Phan, et al. 2001 WR-2721 reduces intestinal toxicity from concurrent Gemcitabine and radiation treatment Int J Pancreatol 29 1 19 23 10.1385/IJGC:29:1:19 10.1385/IJGC:29:1:19 1:CAS:528:DC%2BD3MXmvFKnt7k%3D 11558629
30. B Pauwels, et al. 2003 The radiosensitizing effect of gemcitabine and the influence of the rescue agent amifostine in vitro Eur J Cancer 39 838 46 10.1016/S0959-8049(03)00002-9 10.1016/S0959-8049(03)00002-9 1:CAS:528: DC%2BD3sXitVKgurw%3D 12651211 (Pubitemid 36316002)
31. W Black L Gomez JM Yuhas MM Kligerman 1980 Quantitation of the late effects of X-radiation on the large intestine Cancer 45 444 51 10.1002/1097-0142(19800201)45:3<444::AID-CNCR2820450307>3.0.CO;2-# 10.1002/1097-0142(19800201)45:3<444::AID-CNCR2820450307>3.0.CO;2-# 1:STN:280:DyaL3c7htVyqtA%3D%3D 7353198 (Pubitemid 10169289)
32. A de Lopez Leon M Rojkind 1985 A simple micromethod for collagen and total protein determination informalin-fixed paraffin-embedded sections J Histochem Cytochem 33 737 43
33. Şahinler İ, et al. The effectiveness of amifostine in preventing vaginal fibrosis due to irradiation in rats. 21st Annual ESTRO Meeting, Praha, Czech Republic, 17-21 September, 2002. Radiotherapy and Oncology 2002;64 (Suppl 1).
34. M Hauer-Jensen T Sauer F Devik K Nygaard 1983 Late changes following single dose roentgen irradiation of rat small intestine Acta Radiol Oncol 22 299 303 10.3109/02841868309134045 10.3109/02841868309134045 (Pubitemid 14232796)